1. Nuclear Medicine and Biology
Novel pyridine-containing azacrown-ethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution 
Egorova B.V. , Matazova E.V. , Mitrofanov A.A. , Aleshin G.Yu. , Trigub A.L. , Zubenko A.D. , Fedorova O.A. , Fedorov Yu.V. , Kalmykov S.N.  
Nuclear Medicine and Biology 
Volume 60, Pages 1-10 (May 2018)
DOI: /j.nucmedbio
Copyright © Terms and Conditions

2. Fig. 1
Structures and abbreviated names of ligands investigated in this work L1–L6, and known in literature H4DOTA, H3DO3A-Bu, H5DTPA, H4EDTA, L7.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

3. Fig. 2
Mass-spectra of L6·Bi complex in positive (a) and negative (b) mode.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

4. Fig. 3
1H NMR spectra of a) L6 and b) L6⋅Bi3+ in D2O at pH 2.5 at 298 K.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

5. Fig. 4
Dependence of the extraction of Bi3+ by 0.01 M HDEHP in toluene on ligand concentration in aqueous phase in terms of Eq. (1) for: a) L1, L2 and L3 (pH 3.00 ± 0.05); b) L4 (pH 3.10 ± 0.05 and 4.10 ± 0.05); c) L5 (pH 3.10 ± 0.05 and 4.30 ± 0.05); d) L6 (pH 3.10 ± 0.05).
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

6. Fig. 5
Dependence of D0D−1L on [L] for L2 in terms of Eq. (3) upon extraction by 0.01 M HDEHP in toluene.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

7. Fig. 6
Dependence of Bi3+ concentration in aqueous phase on concentration of ligands L5 (a) and L6 (b) at different pH.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

8. Fig. 7
Dependence of calculated logKapp for L·Bi3+ on pH: a) L1–L3; b) L4–L6.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

9. Fig. 8
Dependence of Kapp on OH– concentration in terms of Eq. (4) for ligands: a) L5; b) L4.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

10. Fig. 9
Relationship between logKBiL and ∑pKa for ligands studied in this work and L7, DOTA and DO3A-Bu.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

11. Fig. 10 Optimized geometry of L6⋅Bi3+ complex in two views.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

12. Fig. 11
The fitted spectrum of X-ray absorption for L6⋅Bi3+ in R- and k-spaces.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

13. Fig. 12
Radiolabeling yield of 207Bi and L6 in ligand's concentrations varying in the range 0.01–1 mM.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions

14. Fig. 13
Time-dependent chelation of 207Bi3+ by serum proteins and its transchelation from complexes with EDTA and L6.
Nuclear Medicine and Biology  , 1-10DOI: ( /j.nucmedbio )
Copyright © Terms and Conditions